HIV Among Drug Users at Beth Israel Medical Center, New York City, the First 25 Years

New York City experienced the first and largest HIV epidemic among injecting drug users (IDUs). Using data collected from IDUs entering the Beth Israel drug detoxification program, we trace the history of this epidemic from the mid-1970s through the early 2000s. The epidemic can best be described in terms of successive stages: (1) introduction and rapid transmission of HIV in the IDU population; (2) stabilization of HIV prevalence at a high level (over 50%); (3) a decline in incidence and prevalence, following large-scale implementation of syringe exchange programs; and (4) a sexual transmission phase, in which HIV prevalence is approximately equal among injecting and noninjecting heroin and cocaine users, and sexual transmission is more important than injecting-related transmission among IDUs. Given the current spread of HIV among IDUs in many places in the world, New York City provides a very strong example for implementation of large-scale comprehensive syringe exchange programs as early as possible in HIV epidemics among IDUs.

[1]  Y. Ruan,et al.  Demographic characteristics and risk behaviors associated with HIV positive injecting drug users in Xinjiang, China. , 2007, The Journal of infection.

[2]  D. D. Des Jarlais,et al.  Effects of outreach intervention on risk reduction among intravenous drug users. , 1990, AIDS education and prevention : official publication of the International Society for AIDS Education.

[3]  S. Friedman,et al.  Working with heroin sniffers: clinical issues in preventing drug injection. , 1990, Journal of substance abuse treatment.

[4]  Susan G. Sherman,et al.  The role of sexual transmission of HIV infection among injection and non-injection drug users , 2003, Journal of Urban Health.

[5]  J Weber,et al.  HIV‐1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987 , 1989, JAMA.

[6]  D. D. Des Jarlais,et al.  The transition from injection to non-injection drug use: long-term outcomes among heroin and cocaine users in New York City. , 2007, Addiction.

[7]  M Beardsley,et al.  Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. , 1998, American journal of public health.

[8]  S. Friedman,et al.  Geographic proximity, policy and utilization of syringe exchange programmes. , 1999, AIDS care.

[9]  D. D. des Jarlais,et al.  "Free" needles for intravenous drug users at risk for AIDS: current developments in New York City. , 1985, The New England journal of medicine.

[10]  Samuel R. Friedman,et al.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. , 1989, JAMA.

[11]  A Munoz,et al.  The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods , 1991, NIDA research monograph.

[12]  D. D. Des Jarlais,et al.  Changes in HIV seroprevalence and related behaviors among male injection drug users who do and do not have sex with men: New York City, 1990-1999. , 2002, American journal of public health.

[13]  S. Friedman,et al.  Prevalence of antibody to lymphadenopathy-associated virus among drug-detoxification patients in New York. , 1984, The New England journal of medicine.

[14]  S. Deren,et al.  Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. , 1995, American journal of epidemiology.

[15]  T. J. Meyer,et al.  Decline in HIV-1 seroprevalence and low seroconversion rate among injecting drug users at a methadone maintenance program in New York City. , 1993, Journal of psychoactive drugs.

[16]  E H Kaplan,et al.  A model-based estimate of HIV infectivity via needle sharing. , 1992, Journal of acquired immune deficiency syndromes.

[17]  R. Hogg,et al.  Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  D. D. Des Jarlais,et al.  Maintaining low HIV seroprevalence in populations of injecting drug users. , 1995, JAMA.

[19]  D. Vlahov,et al.  Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. , 1995, Archives of internal medicine.

[20]  Don C Des Jarlais,et al.  Transitions to Injecting Drug Use Among Noninjecting Heroin Users: Social Network Influence and Individual Susceptibility , 2006, Journal of acquired immune deficiency syndromes.

[21]  M. Gottlieb,et al.  Pneumocystis pneumonia--Los Angeles. , 2006, MMWR. Morbidity and mortality weekly report.

[22]  H. Wolfe,et al.  Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. , 1994, AIDS research and human retroviruses.

[23]  D. D. Des Jarlais,et al.  Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. , 2009, Drug and alcohol dependence.

[24]  Don C Des Jarlais,et al.  HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. , 2005, American journal of public health.

[25]  B. Stepherson,et al.  Heroin sniffers: between two worlds. , 1988, Journal of psychoactive drugs.

[26]  W. El-Sadr,et al.  Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. , 1987, AIDS.

[27]  L. Torian,et al.  Estimates of HIV Incidence Among Persons Testing for HIV Using the Sensitive/Less Sensitive Enzyme Immunoassy, New York City, 2001 , 2005, Journal of acquired immune deficiency syndromes.

[28]  W. Anderson,et al.  The New York Needle Trial: the politics of public health in the age of AIDS. , 1991, American journal of public health.

[29]  J. Montaner,et al.  Frequent needle exchange use and HIV incidence in Vancouver, Canada. , 2007, The American journal of medicine.

[30]  D. Mildvan,et al.  A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City , 1988, Science.

[31]  S. Friedman,et al.  AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. , 1994, American journal of public health.

[32]  D. D. Des Jarlais,et al.  “Informed Altruism” and “Partner Restriction” in the Reduction of HIV Infection in Injecting Drug Users Entering Detoxification Treatment in New York City, 1990–2001 , 2004, Journal of acquired immune deficiency syndromes.

[33]  S. Friedman,et al.  Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users , 2004, Journal of Urban Health.

[34]  Calle Ee,et al.  Leukemia in occupational groups with presumed exposure to electrical and magnetic fields. , 1985 .

[35]  D. D. Des Jarlais,et al.  Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. , 2009, American journal of public health.

[36]  S. Friedman,et al.  Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. , 2000, American journal of public health.

[37]  D. D. Des Jarlais,et al.  AIDS and the transition to illicit drug injection--results of a randomized trial prevention program. , 1992, British journal of addiction.

[38]  R. Coutinho,et al.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.

[39]  D. Vlahov,et al.  Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. , 2001, American journal of public health.

[40]  D. Vlahov,et al.  Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (hiv) epidemic in new york city , 1989, Journal of medical virology.

[41]  A. Abdul-Quader,et al.  Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City , 2007, AIDS.

[42]  S. Friedman,et al.  Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. , 1985, Annals of internal medicine.

[43]  K. Fischer,et al.  High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia , 2007, International journal of STD & AIDS.

[44]  D. D. Des Jarlais,et al.  HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. , 2000, American journal of public health.

[45]  P. Bacchetti,et al.  Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis , 2001, The Lancet.

[46]  M. Hellard,et al.  The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia. , 2004, AIDS Research and Human Retroviruses.

[47]  S. Holmberg,et al.  Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. , 1994, The New England journal of medicine.

[48]  A. Abdul-Quader,et al.  The AIDS epidemic among blacks and Hispanics. , 1987, The Milbank quarterly.